ATE284969T1 - Rekombinante adenovirale vektoren, die eine spleissequenz enthalten - Google Patents

Rekombinante adenovirale vektoren, die eine spleissequenz enthalten

Info

Publication number
ATE284969T1
ATE284969T1 AT98928412T AT98928412T ATE284969T1 AT E284969 T1 ATE284969 T1 AT E284969T1 AT 98928412 T AT98928412 T AT 98928412T AT 98928412 T AT98928412 T AT 98928412T AT E284969 T1 ATE284969 T1 AT E284969T1
Authority
AT
Austria
Prior art keywords
splicing sequence
host cell
adenoviral vector
concerns
recombinant adenoviral
Prior art date
Application number
AT98928412T
Other languages
English (en)
Inventor
Majid Mehtali
Pierre Leroy
Anne-Isabelle Michou
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE284969T1 publication Critical patent/ATE284969T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Tyre Moulding (AREA)
  • Image Processing (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Communication Control (AREA)
AT98928412T 1997-06-02 1998-06-02 Rekombinante adenovirale vektoren, die eine spleissequenz enthalten ATE284969T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9706757A FR2763959A1 (fr) 1997-06-02 1997-06-02 Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
PCT/FR1998/001105 WO1998055639A2 (fr) 1997-06-02 1998-06-02 Vecteurs adenoviraux recombinants comprenant une sequence d'epissage

Publications (1)

Publication Number Publication Date
ATE284969T1 true ATE284969T1 (de) 2005-01-15

Family

ID=9507493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98928412T ATE284969T1 (de) 1997-06-02 1998-06-02 Rekombinante adenovirale vektoren, die eine spleissequenz enthalten

Country Status (12)

Country Link
US (1) US6399587B1 (de)
EP (1) EP0988391B1 (de)
JP (1) JP4386971B2 (de)
AT (1) ATE284969T1 (de)
AU (1) AU753809B2 (de)
CA (1) CA2292792C (de)
DE (1) DE69828167T2 (de)
DK (1) DK0988391T3 (de)
ES (1) ES2232950T3 (de)
FR (1) FR2763959A1 (de)
PT (1) PT988391E (de)
WO (1) WO1998055639A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434689D1 (de) 1993-06-10 2006-05-18 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
IL126757A0 (en) * 1998-09-07 1999-08-17 Yissum Res Dev Co Regulation of gene expression through manipulation of mRNA splicing and its uses
EP1048736A1 (de) 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-Konstrukt für die Gewebespezifischen Expression eines Blutkoagulationsfaktors
EP1048726B1 (de) * 1999-04-27 2006-07-26 Négrier, Claude Modifizierte Faktor VIII cDNA
EP1038959A1 (de) * 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
WO2001011066A1 (de) * 1999-08-06 2001-02-15 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Nicht-humaner adenoviraler vektor für den gentransfer, seine anwendung und seine herstellung
CA2415347A1 (en) * 2000-07-14 2002-01-24 University Of Saskatchewan Adenovirus vectors comprising introns
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
US20030026783A1 (en) * 2001-08-03 2003-02-06 Amine Abina Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins
EP1283263A1 (de) * 2001-08-08 2003-02-12 Aventis Behring GmbH Modifizierte cDNA für die erhöhte Expression von Faktor VIII und seinen Derivaten
EP1284290A1 (de) * 2001-08-08 2003-02-19 Aventis Behring GmbH Erhöhung der Expression von Faktor VIII durch Insertion von spleissbaren Nukleotidsequenzen in Faktor VIII cDNA
ITMI20012110A1 (it) * 2001-10-12 2003-04-12 Keryos Spa Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
AU2002365084A1 (en) * 2001-10-19 2003-07-24 Sirna Therapeutics, Inc Method and reagent for the detection of proteins and peptides
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
EP1802336B1 (de) * 2004-10-14 2011-09-07 Crucell Holland B.V. Prime-boost-impfstoffe gegen malaria
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
ES2704677T3 (es) * 2013-04-18 2019-03-19 Fond Telethon Suministro eficaz de genes grandes por vectores de AAV duales
KR102252423B1 (ko) * 2019-02-22 2021-05-13 알지노믹스 주식회사 암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518913A (en) * 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
EP0911413A3 (de) * 1992-12-03 2000-11-15 Genzyme Corporation Mindestadenovirus-Vector zur Gentherapie
AU4362993A (en) 1993-04-23 1994-11-21 Eliasson, Torbjorn Disposable waterproof covering
DE69434689D1 (de) * 1993-06-10 2006-05-18 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
WO1995016772A1 (en) * 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
EP0821739B1 (de) * 1995-04-17 2003-06-18 The Board Of Regents, The University Of Texas System Adenovirus helfervirus system
FR2737222B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique

Also Published As

Publication number Publication date
DE69828167D1 (de) 2005-01-20
CA2292792A1 (fr) 1998-12-10
DE69828167T2 (de) 2005-12-22
DK0988391T3 (da) 2005-07-25
US6399587B1 (en) 2002-06-04
AU8024798A (en) 1998-12-21
ES2232950T3 (es) 2005-06-01
PT988391E (pt) 2005-05-31
CA2292792C (fr) 2010-03-30
WO1998055639A2 (fr) 1998-12-10
EP0988391B1 (de) 2004-12-15
JP4386971B2 (ja) 2009-12-16
JP2002511751A (ja) 2002-04-16
WO1998055639A3 (fr) 1999-03-04
FR2763959A1 (fr) 1998-12-04
EP0988391A2 (de) 2000-03-29
AU753809B2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
ATE284969T1 (de) Rekombinante adenovirale vektoren, die eine spleissequenz enthalten
ATE214100T1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
DE69535103D1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
ATE236263T1 (de) Adeno-assozierter virus 2 basalvektoren
DK0707071T3 (da) Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi
CA2161962A1 (en) Adenovirus vectors for gene therapy
PT728214E (pt) Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
MX9709549A (es) Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen.
DK0738327T3 (da) Vært-vektorsystem til anvendelse ved genterapi
ES2164260T3 (es) Vectores virales para la terapia genica.
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
ATE315087T1 (de) Neuartige auf p53 ansprechende gene
DK0632129T3 (da) Rekombinante foamy-virusvektorer til medicinsk og diagnostisk anvendelse, og fremgangsmåder til at præparere rekombinante foamy-virusvektorer
CA2309755A1 (en) Hormone-dependent forms of the adeno-associated virus, rep proteins, dna sequences coding for them, vectors containing them, and regulatory methods of their intracellular activity
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
BR9813917A (pt) Vetores de expressão induzìveis hipertérmicospara terapia de genetica e métodos de uso dos mesmos
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
DK0843731T3 (da) Adenovirusvektorer til genterapi
KR970706397A (ko) IV a2 유전자가 불활성화된 결손 재조합 아데노바이러스(DEFECTIVE RECOMBINANT ADENOVIRUSES WITH AN INACTIVATED IV a2 GENE)
ATE264398T1 (de) Regulierte expression von proteinen in stabil transformierten säugetierzellen
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
IL87394A0 (en) Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing said vectors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0988391

Country of ref document: EP